|
|
Taiwan Academic Institutional Repository >
Browse by Title
|
Showing items 654201-654225 of 2307984 (92320 Page(s) Totally)
<< < 26164 26165 26166 26167 26168 26169 26170 26171 26172 26173 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2018-09-10T03:49:28Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
MING-SHIOU WU; Chen, A.-L. and Hsu, C.-H. and Lin, J.-K. and Hsu, M.-M. and Ho, Y.-F. and She, T.-S. and Ko, J.-Y. and Lin, J.-T. and Lin, B.-R. and Wu, M.-S. and Yu, H.-S. and Jee, S.-H. and Chen, G.-S. and Chen, T.-M. and Chen, C.-A. and Lai, M.-K. and Pu, Y.-S. and Pan, M.-H. and Wang, Y.-J. and Tsai, C.-C. and Hsieh, C.-Y. |
| 臺大學術典藏 |
2018-09-10T03:44:41Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
MIN-HSIUNG PAN; MIN-HSIUNG PAN |
| 臺大學術典藏 |
2020-01-22T07:50:53Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; CHI-AN CHEN; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y.; Lin J.-K.; Hsu C.-H.; Chen A.-L.; Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chi-An Chen;Lai M.-K.;Pu Y.-S.;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y. |
| 臺大學術典藏 |
2020-11-02T02:05:31Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Hsieh C.-Y.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Ho Y.-F.; Hsu M.-M.; Lin J.-K.; Hsu C.-H.; Chen A.-L. |
| 臺大學術典藏 |
2021-10-25T02:57:41Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L; |Hsu C.-H; |Lin J.-K; |Hsu M.-M; |Ho Y.-F; |She T.-S; |JENG-YUH KO; |Lin J.-T; |Lin B.-R; |Wu M.-S; |Yu H.-S; |Jee S.-H; |Chen G.-S; |Chen T.-M; |Chen C.-A; |Lai M.-K; |Pu Y.-S; |Pan M.-H; |Wang Y.-J; |Tsai C.-C; |Hsieh C.-Y. |
| 臺大學術典藏 |
2021-11-18T04:58:19Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L; Hsu C.-H; Lin J.-K; Hsu M.-M; Ho Y.-F; She T.-S; JENG-YUH KO; Lin J.-T; Lin B.-R; Wu M.-S; Yu H.-S; Jee S.-H; Chen G.-S; Chen T.-M; Chen C.-A; Lai M.-K; Pu Y.-S; Pan M.-H; Wang Y.-J; Tsai C.-C; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-11-15T07:48:43Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L; Hsu C.-H; Lin J.-K; Hsu M.-M; Ho Y.-F; She T.-S; JENG-YUH KO; Lin J.-T; Lin B.-R; Wu M.-S; Yu H.-S; Jee S.-H; Chen G.-S; Chen T.-M; Chen C.-A; Lai M.-K; Pu Y.-S; Pan M.-H; Wang Y.-J; Tsai C.-C; Hsieh C.-Y. |
| 國家衛生研究院 |
2021-03-01 |
Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
|
Tsai, HJ;Shiah, HS;Chang, JY;Su, WC;Chiang, NJ;Chen, LT |
| 國立成功大學 |
2021-03-1 |
Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
|
Tsai;Hui-Jen;Shiah;Her-Shyong;Chang;Jang-Yang;Su;Wu-Chou;Chiang;Nai-Jung;Chen;Li-Tzong |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
|
Ansell P; Motwani M; Wong S; Yue H; Wang L; Reilly E; Afar D; Naumovski L; Ramanathan R.K.; Strickler J.H; LoRusso P; Salgia R; Kang Y.-K; Yen C.J; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; Chia-Chi Lin; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. |
| 國立成功大學 |
2020 |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler, J.H.;LoRusso, P.;Salgia, R.;Kang, Y.-K.;Yen, C.J.;Lin, C.-C.;Ansell, P.;Motwani, Motwani M.;Wong, S.;Yue, H.;Wang, L.;Reilly, E.;Afar, D.;Naumovski, L.;Ramanathan, Ramanathan R.K. |
| 國家衛生研究院 |
2020-11-27 |
Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors
|
Shiah, HS;Chiang, NJ;Lin, CC;Yen, CJ;Tsai, HJ;Wu, SY;Su, WC;Chang, KY;Wang, CC;Chang, JY;Chen, LT |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah H.-S.; Chiang N.-J.; Chia-Chi Lin; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. |
| 國立成功大學 |
2021 |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah, H.-S.;Chiang, N.-J.;Lin, C.-C.;Yen, C.-J.;Tsai, H.-J.;Wu, S.-Y.;Su, W.-C.;Chang, K.-Y.;Wang, C.-C.;Chang, J.-Y.;Chen, L.-T. |
| 國家衛生研究院 |
2016-02 |
Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors
|
Tsai, HJ;Chiang, NJ;Shiah, HS;Chang, KY;Su, WC;Chang, JY;Chen, LT |
| 國立成功大學 |
2016-02-01 |
Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors.
|
Tsai, Hui-Jen; Chiang, Nai-Jung; Shiah, Her-Shyong; Chang, Kwang-Yu; Su, Wu-Chou; Chang, Jang-Yang; Chen, Li-Tzong |
| 國立臺灣大學 |
2011 |
Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics
|
陳培哲; CHEN, PEI-JER |
| 臺大學術典藏 |
2021-07-03T03:34:34Z |
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics
|
Yau T.; PEI-JER CHEN; Chan P.; Curtis C.M.; Murphy P.S.; Suttle A.B.; Gauvin J.; Hodge J.P.; Dar M.M.; Poon R.T. |
| 臺大學術典藏 |
2018 |
Phase I investigator's perceptions to 'supersized seamless trials in oncology'
|
Ma B.B.Y; van der Velden N; Mo F; Loong H.H; Siu L; Goh B.C; Bang Y.-J; Chia-Chi Lin; Desai J; Lolkema M.P. |
| 中山醫學大學 |
2021 |
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation
|
Park, K; Chang, GC; Curigliano, G; Lim, WT; Soo, RA; Molina-Vila, MA; Cattan, V; Darville, H; Gandossi, E; Smutna, V; Sudey, I; Viteri, S |
| 國家衛生研究院 |
2013-12 |
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
|
Finn, RS;Poon, RTP;Yau, T;Klümpen, HJ;Chen, LT;Kang, YK;Kim, TY;Gomez-Martin, C;Rodriguez-Lope, C;Kunz, T;Paquet, T;Brandt, U;Sellami, D;Bruix, J |
| 國家衛生研究院 |
2021-03-30 |
Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia
|
Tsai, HJ;Hsiao, HH;Hsu, YT;Liu, YC;Kao, HW;Liu, TC;Cho, SF;Feng, X;Johnston, A;Bomalaski, JS;Kuo, MC;Chen, TY |
| 國立成功大學 |
2021-05 |
Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia
|
Tsai;Hui-Jen;Hsiao;Hui-Hua;Hsu;Ya-Ting;Liu;Yi-Chang;Kao;Hsiao-Wen;Liu;Ta-Chih;Cho;Shih-Feng;Feng;Xiaoxing;Johnston;Amanda;Bomalaski;John, S.;Kuo;Ming-Chung;Chen;Tsai-Yun |
| 國家衛生研究院 |
2020-05 |
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer
|
Yoo, C;Oh, DY;Choi, HJ;Kudo, M;Ueno, M;Kondo, S;Chen, LT;Osada, M;Helwig, C;Dussault, I;Ikeda, M |
Showing items 654201-654225 of 2307984 (92320 Page(s) Totally)
<< < 26164 26165 26166 26167 26168 26169 26170 26171 26172 26173 > >>
View [10|25|50] records per page
|
